• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia

Trendingnow

1

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic

2

‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion

3

Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard

1

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic

2

‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion

3

Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard
HealthWeight Loss

Most Americans who want to lose weight don’t want to take GLP-1 drugs like Wegovy and Zepbound, new survey says

By
Lindsey Leake
Lindsey Leake
Down Arrow Button Icon
By
Lindsey Leake
Lindsey Leake
Down Arrow Button Icon
October 10, 2024, 10:00 AM ET
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.
Despite the ubiquitousness of injectable GLP-1 drugs indicated for people with obesity, most Americans wouldn’t take them, according to a September 2024 survey from the Physicians Committee for Responsible Medicine.Choi Dongsu—Getty Images
Add Fortune on Google for similar content.

GLP-1s, or glucagon-like peptide-1 agonist drugs, are seemingly everywhere. In recent years, this class of weight-loss and Type 2 diabetes medication has become not only a household name but inescapable. Shortages have dominated news headlines, and singsong commercials have taken over airwaves. GLP-1s have gone so far as to disrupt the food, clothing, and, of course, weight-loss industries.

Recommended Video

Yet despite the ubiquitousness of injectable drugs indicated for people with obesity—such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide)—most Americans wouldn’t take them, according to a new survey.

The nonprofit Physicians Committee for Responsible Medicine teamed up with business intelligence firm Morning Consult to survey more than 2,200 U.S. adults about weight-loss methods. Results of the poll, conducted in September, were released Oct. 8.

People were asked to rate their level of agreement with this statement: “If I wanted to lose weight, I would rather take an injectable weight-loss drug, rather than make a diet change.” More than half (62%) disagreed, with 14% reporting the statement didn’t apply to them because they don’t need to lose weight. Nearly three-fourths (73%) of applicable respondents disagreed.

Among people who were interested in weight loss, these groups most strongly disagreed:

  • Men: 75%
  • Baby boomers: 78%
  • Asian or “other”: 77%
  • Postgraduate-degree holders: 79%
  • Household income exceeds $100K: 78%
  • Urban dwellers: 75%
  • Northeasterners: 77%
  • Registered voters: 73%
  • Independent voters: 74%

“The new findings do not mean that Americans do not want to lose weight,” PCRM president Dr. Neal Barnard said in a news release about the survey. “Rather, most would prefer to change their eating habits than inject a medication.”

While the results offer a snapshot of public opinion, the question doesn’t capture the nuances of healthy weight loss. A calorie deficit is a critical component of weight loss but ultimately just one piece of the puzzle. Genes, sleep, stress, hormones, physical activity, and certain medications can impact weight management. Your medical history also plays a role. What’s more, GLP-1s approved for people with obesity are intended for patients who’ve had difficulty losing weight by other means, and designed to be taken in conjunction with diet and exercise.

Dr. Nisha Patel, medical director of the Obesity Medicine and Metabolic Health Program within the transplant department at California Pacific Medical Center in San Francisco, is working to dispel the myth that taking weight-loss medication is the easy way out.

“People forget that there are some strong neurohormonal factors at play that make it difficult to not only lose weight, but to keep that weight off in the long term,” Patel previously told Fortune. “Medications have really helped level the playing field. It can help interrupt some of that disruptive signaling.”

That said, GLP-1 adherence is an issue. According to a research brief published in the August issue of the Journal of Managed Care and Specialty Pharmacy, roughly one in three (32%) patients were still on their medication after a year. Fewer than that (27%) took the drug as intended.

Plant-based diet appeals to weight-loss hopefuls

The PCRM survey also asked people how much they agreed with this statement: “If a plant-based diet might cause significant weight loss, I would be interested in trying it, at least briefly.” More than half (57%) of all respondents agreed, with 17% saying they didn’t need to lose weight. More than three in five (68%) respondents looking to lose weight agreed.

Among people who were interested in weight loss, these groups most strongly agreed:

  • Women: 70%
  • Gen Zers: 81%
  • Asian or “other”: 76%
  • College and postgraduate-degree holders (tie): 69%
  • Household income exceeds $100K: 70%
  • Urban dwellers: 75%
  • Northeasterners: 70%
  • Registered voters: 69%
  • Democrats: 76%

For more on weight management:

  • Hims & Hers Super Bowl ad slams pricey pharma industry—and fumbles FDA warnings on compounded GLP-1 drugs
  • Zepbound vs. Wegovy: New clinical trial says this weight-loss medication sheds more pounds
  • The 5 biggest weight loss myths that ‘need to die,’ according to an obesity doctor
  • GLP-1 drugs like Wegovy are all the rage—but people are quitting them too fast to achieve meaningful weight loss, finds 170,000-patient study
  • This is the best time of day to exercise for people living with obesity, new study shows

Subscribe to Well Adjusted, our newsletter full of simple strategies to work smarter and live better, from the Fortune Well team. Sign up for free today.

About the Author
By Lindsey Leake
LinkedIn iconTwitter icon
See full bioRight Arrow Button Icon
Add Fortune on Google for similar content.

Latest in Health

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Fortune Editors
October 20, 2025
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Latest in Health

Ferran Torres
SuccessWorld Cup
Spain’s Ferran Torres scored the winning goal in the World Cup—but just four years ago, he was in therapy and stuck in a ‘bottomless pit’
By Emma BurleighJuly 20, 2026
6 hours ago
FDA walks back positive lab test while lettuce recall continues
HealthFood and drink
FDA walks back positive lab test while lettuce recall continues
By Bloomberg, Kristina Peterson, Jessica Nix and Daniela SirtoriJuly 20, 2026
7 hours ago
Pharmacy technician Brandy Leroy fills a TPN bag using the ExactaMix Pro Automated Compounding System
Startups & VentureTerm Sheet
The FDA’s peptide vote could create telehealth’s next multibillion-dollar market
By Lily Mae LazarusJuly 20, 2026
10 hours ago
A decade after the ‘Godfather of AI’ said radiologists were obsolete, their salaries are up to $571K and demand is growing fast
AIthe future of work
A decade after the ‘Godfather of AI’ said radiologists were obsolete, their salaries are up to $571K and demand is growing fast
By Marco Quiroz-GutierrezJuly 19, 2026
1 day ago
How United’s ‘premiumization’ strategy got passengers to swallow higher airfares without a fight
HealthAirline industry
How United’s ‘premiumization’ strategy got passengers to swallow higher airfares without a fight
By Phil WahbaJuly 19, 2026
2 days ago
Diarrhea-causing lettuce may have spread as wide as 27 states, Taylor Farms recall suggests
HealthFood and drink
Diarrhea-causing lettuce may have spread as wide as 27 states, Taylor Farms recall suggests
By Savannah Peters and The Associated PressJuly 18, 2026
2 days ago

Most Popular

'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic
AI
'Dr. Doom' Nouriel Roubini says we're headed for universal basic income or 'some form of socialism' as AI revolutionizes work—He calls that optimistic
By Jason MaJuly 18, 2026
2 days ago
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion
Success
‘I want to die broke’: Billionaire philanthropist Denny Sanford dies after giving away $4 billion
By Sydney LakeJuly 20, 2026
8 hours ago
Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard
AI
Power companies are using eminent domain to seize land for data centers as 70% of Americans say not in my backyard
By Aaron Walayat and The ConversationJuly 19, 2026
2 days ago
Red Lobster’s 37-year-old CEO waited tables before joining the C-suite—he says it was a crash course in managing ‘difficult people and situations’
Success
Red Lobster’s 37-year-old CEO waited tables before joining the C-suite—he says it was a crash course in managing ‘difficult people and situations’
By Preston ForeJuly 19, 2026
2 days ago
Warren Buffett says his $147 billion investing career was an accident: ‘I may be one of the 10 luckiest in the world’
Future of Work
Warren Buffett says his $147 billion investing career was an accident: ‘I may be one of the 10 luckiest in the world’
By Sarah GlodekJuly 20, 2026
14 hours ago
It’s not just Taco Bell lettuce and possible glass in Pillsbury rolls: Food and drink recall events reached a 6-year year-over-year high
Retail
It’s not just Taco Bell lettuce and possible glass in Pillsbury rolls: Food and drink recall events reached a 6-year year-over-year high
By Sasha RogelbergJuly 20, 2026
11 hours ago

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.